In order to produce high yields of astatine-211 without contamination of chloride ions, provided is a method for producing astatine-211, including (1) a step of generating astatine-211 by irradiating bismuth with α rays; (2) a step of heating the astatine-211 generated in step (1) to vaporize; (3) a step of cooling the astatine-211 that has been vaporized in step (2) and collecting the astatine-211 with a volatile and polar solvent to obtain an astatine-211 solution; (4) a step of adding a weak acid salt to the astatine-211 solution obtained in step (3) to obtain an astatine-211 solution containing the weak acid salt; and (5) a step of removing the solvent from the astatine-211 solution containing the weak acid salt obtained in step (4).

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R.sub.1 and R.sub.2 are each independently for each occurrence optionally substituted C.sub.10-C.sub.30 alkyl, optionally substituted C.sub.10-C.sub.30 alkenyl, optionally substituted C.sub.10-C.sub.30 alkynyl, optionally substituted C.sub.10-C.sub.30 acyl, or -linker-ligand; R.sub.3 is H, optionally substituted C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.2-C.sub.10 alkenyl, optionally substituted C.sub.2-C.sub.10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.

##STR00001##

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R.sub.1 and R.sub.2 are each independently for each occurrence optionally substituted C.sub.10-C.sub.30 alkyl, optionally substituted C.sub.10-C.sub.30 alkenyl, optionally substituted C.sub.10-C.sub.30 alkynyl, optionally substituted C.sub.10-C.sub.30 acyl, or -linker-ligand; R.sub.3 is H, optionally substituted C.sub.1-C.sub.10 alkyl, optionally substituted C.sub.2-C.sub.10 alkenyl, optionally substituted C.sub.2-C.sub.10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.

##STR00001##

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process. ##STR00001##

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process. ##STR00001##

A liquid-crystalline medium having a nematic phase containing one or more compounds of formula D ##STR00001##
the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type and the use of the compounds of formula D for improvement of the contrast and/or response times of a liquid-crystalline medium which contain one or more additional mesogenic compounds, as well as certain compounds of formula D.

A liquid-crystalline medium having a nematic phase containing one or more compounds of formula D ##STR00001##
the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type and the use of the compounds of formula D for improvement of the contrast and/or response times of a liquid-crystalline medium which contain one or more additional mesogenic compounds, as well as certain compounds of formula D.

The invention relates to resorcinol-derived compounds of formula (I) and also the salts thereof, the solvates thereof and the optical and/or geometrical isomers thereof, including enantiomers and diastereoisomers, the racemic mixtures thereof, alone or as a mixture. The invention also relates to a cosmetic process for depigmenting, lightening and/or bleaching keratin materials, in particular the skin, using these compounds (I).

The invention relates to resorcinol-derived compounds of formula (I) and also the salts thereof, the solvates thereof and the optical and/or geometrical isomers thereof, including enantiomers and diastereoisomers, the racemic mixtures thereof, alone or as a mixture. The invention also relates to a cosmetic process for depigmenting, lightening and/or bleaching keratin materials, in particular the skin, using these compounds (I).

The present disclosure provides a side chain liquid crystal epoxy monomer (S-LCEM) and a preparation method thereof, and a side chain liquid crystal epoxy resin (S-LCER) with high intrinsic thermal conductivity, and belongs to the technical field of epoxy resin materials. There are biphenyl mesogenic groups with strong rigidity in a molecular structure of the S-LCEM provided in the present disclosure and there are also flexible connections among chain segments, which promotes the ordered arrangement of S-LCEM molecular chains during a curing process. The highly-ordered arrangement of such mesogenic units is conducive to the formation of a local crystalloid structure, so that a heat flow is transferred along a direction of the ordered molecular chain, which effectively inhibits the scattering of phonons in the S-LCER with high intrinsic thermal conductivity and greatly improves the intrinsic thermal conductivity of the S-LCER with high intrinsic thermal conductivity.